| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Review |
From the Department of Pathology and Laboratory Medicine,* Joan and Sanford I. Weill Medical College of Cornell University, New York, New York; and the Department of Biomolecular Chemistry, University of Wisconsin Medical School, Madison, Wisconsin
Abstract
MicroRNAs (miRNAs) are a family of 21- to 25-nucleotide, noncoding small RNAs that primarily function as gene regulators. It is surprising that these tiny molecules, so diverse and consequential in their biological functions, have been hidden for so many years. Thanks to their discovery, cancer research has found a new arena. Aided by innovative molecular techniques, the research of miRNAs in oncology has progressed rapidly in recent years. miRNA abnormalities are becoming an emerging theme in cancer research. Specific functions of miRNAs, many of which are relevant to cancer development, are becoming apparent. The value of miRNAs in cancer classification and prognostication is being explored, and new therapeutic strategies targeting miRNAs are being developed. Because there is great promise that miRNA research will provide breakthroughs in the understanding of cancer pathogenesis and development of new valuable prognostic markers, pathologists should be adequately informed of this rapidly progressing field. Here, we offer a review on the basics of miRNA biology and the emerging role of miRNA in cancer pathogenesis, classification, and prognostication, including highlights of the involvement of specific miRNAs in different tumor types.
This article has been cited by other articles:
 |
|
 |
|
  N. Dahiya and P. J Morin MicroRNAs in ovarian carcinomas Endocr. Relat. Cancer, March 1, 2010; 17(1): F77 - F89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-L. Ng, H.-C. Liu, and S.-C. Lee ncRNAppi--a tool for identifying disease-related miRNA and siRNA targeting pathways Bioinformatics, December 1, 2009; 25(23): 3199 - 3201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S M Metias, E Lianidou, and G M Yousef MicroRNAs in clinical oncology: at the crossroads between promises and problems J. Clin. Pathol., September 1, 2009; 62(9): 771 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Cochrane, N. S. Spoelstra, E. N. Howe, S. K. Nordeen, and J. K. Richer MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents Mol. Cancer Ther., May 1, 2009; 8(5): 1055 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Wu, P.-Y. Law, L.-N. Wei, and H. H. Loh Post-transcriptional regulation of mouse {micro} opioid receptor (MOR1) via its 3' untranslated region: a role for microRNA23b FASEB J, December 1, 2008; 22(12): 4085 - 4095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Tam The Emergent Role of MicroRNAs in Molecular Diagnostics of Cancer J. Mol. Diagn., September 1, 2008; 10(5): 411 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nie, M. Gomez, P. Landgraf, J.-F. Garcia, Y. Liu, L. H.C. Tan, A. Chadburn, T. Tuschl, D. M. Knowles, and W. Tam MicroRNA-Mediated Down-Regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg Cells: A Potential Pathogenetic Lesion in Hodgkin Lymphomas Am. J. Pathol., July 1, 2008; 173(1): 242 - 252. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
